Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence

By R. Dent, M. Trudeau, K. Pritchard, W. Hanna, H. Kahn, C. Sawka, L. Lickley, E. Rawlinson, P. Sun, S. Narod. Clinical Cancer Research, 2007

4,710 citations recorded by the source corpus.

Subfields: Cancer Research, Epidemiology, Oncology

View Paper: https://www.semanticscholar.org/paper/623d56600e2bac528db05270048e03c7a6107aae

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. N. Almansour
2. J. Reis-Filho
3. Joseph R. Nevins
4. X. Chen
5. Lisa A. Carey
6. Andrew Tutt
7. M. Moynahan

In Epidemiology

1. X. Chen

In Oncology

1. N. Almansour
2. J. Reis-Filho
3. Peter K. Sorger
4. M. Moynahan
5. A. Damjanović
6. C. Hudis
7. S. Tolaney
8. M. Nedeljković

Citations in the corpus

• Triple-negative breast cancer--current status and future directions. (2009, background): “The aggressiveness of TNBC is further indicated by the fact that (i) the peak risk of recurrence occurs within the first 3 years after initial treatment of the disease with the majority of deaths occurring in the first 5 years [18, 42] and (ii) after diagnosis of metastatic disease, a significantly ”
• Triple-Negative Breast Cancer: A Brief Review About Epidemiology, Risk Factors, Signaling Pathways, Treatment and Role of Artificial Intelligence (2022, background): “Additionally, these cancers have characteristic metastatic patterns and poor prognosis (Dent et al., 2007).”
• Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer (2013, background): “Eight patients whose tumors tested AR+ were ineligible for treatment due to testing ER(+) centrally (2), developing a second primary cancer (1), not meeting all of the prespecified eligibility criteria (2), or having a significant decline in performance status (3).”
• Triple-negative breast cancer molecular subtyping and treatment progress (2020, background): “Compared with other subtypes of breast cancer, the survival time of TNBC patients is shorter, and the mortality rate is 40% within the first 5 years after diagnosis [7].”
• An overview of triple-negative breast cancer (2016, background): “In contrast, more than 50 % ER-positive breast cancers recur between 5 and 10 years after surgery, and in the long term more events will occur in high-grade ER-positive breast cancers as compared to TNBC [6, 55, 74, 75].”
• Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. (2011, background): “1 70 (80) and lymph node–negative patients that developed a distant metastasis (106) treated at Erasmus Medical Center GSE-2990A Sweden, Invasive breast cancer from Uppsala, Sweden 189 ER 11 (6) 1.”
• Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment (2019, neutral): “AKT signaling PIK3CA (24), AKT1 (2), PTEN (4), PIK3R1 (3), FOXO3 (1) Cell-cycle regulation RB1 (4), CDKN2A (1) Chromatin function KMT2C (9), ARID1A (3), NCOR1 (2), PBRM1 (3), KDM6A (2) DNA damage and apoptosis TP53 (77), BRCA1 (3), BRCA2 (3) MAPK signaling NF1 (4), MAP3K1 (3), MAP2K4 (1), KRAS (1) T”